Company intelligence / Profile preview
Enzymatica
Lund, Swedenenzymatica.com ↗
- Ownership
- Private
- Employees
- ~21
- Development stage
- Commercial
01
Overview
Enzymatica’s lead product ColdZyme® mouth spray has demonstrated in several independent clinical studies that it can reduce the duration and severity of common cold symptoms by lowering viral load in the upper respiratory tract. Recent peer-reviewed publications confirm efficacy and high customer satisfaction; over nine out of ten users intend to repurchase.
- Therapeutic areas
- DermatologyInfectious Diseases
- Modalities
- ProteinDevice
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Not specifically named in public sources; company strategy focuses on global expansion via established partners/distributors
Beyond the preview
Go deeper on Enzymatica.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enzymatica.